EZH2 and AL amyloidosis: While the efficacy of EZH2 inhibitors in RMC is still unknown, several small‐scale studies have demonstrated a response with bortezomib or platinum‐based combination chemotherapies, such as MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin).6, 17, 18, 19 Bortezomib is a known anticancer medication that is currently used to treat multiple myeloma and mantle cell lymphoma and targets the ubiquitin‐proteasome pathway (UPP) by binding the catalytic site of the 26S proteasome.